Background: Fewer than 20% of patients with bone cancer who are treated with surgery alone are cured. Even with the best current treatment, surgery combined with chemotherapy, only 60%-80% of patients with nonmetastatic bone cancer and 10% of patients with metastatic bone cancer are cured. Thus far, the reason for treatment failure in the nonresponding subset has not been identified. It has been hypothesized that P-glycoprotein, which confers multidrug resistance, might be the cause. We sought to determine whether the expression of P-glycoprotein is associated with poor treatment outcome in osteosarcoma. Methods: In a retrospective study, we correlated P-glycoprotein expression with the outcome of conventional chemotherapy in 62 consecutive, clinically staged patients diagnosed as having osteosarcoma between 1980 and 1989. Results: P-glycoprotein was overexpressed in 27 patients but not in another 34 patients, and expression was ambiguous in the sample from one patient. At a median follow-up of 8.9 years, the 34 patients whose tumors did not express P-glycoprotein had significantly better relapse-free rates than the 27 subjects whose tumors expressed the protein (87% versus 0%; P<.00001) and had improved survival rates (94% versus 35%; P<.00001). Among the 46 patients who received chemotherapy before surgery, the 23 whose tumors were negative for P-glycoprotein showed significantly better long-term outcomes (P<.00002), although differences in tumor necrosis in response to therapy were only of borderline significance (P = .057). Conclusions: P-glycoprotein expression does correlate with treatment failure in patients with osteosarcoma. This correlation raises the possibility that inhibiting the action of P-glycoprotein as part of therapy for this disease would improve outcome. [J Natl Cancer Inst 1997;89:1706-15]
Treatment
We treated 59 patients surgically (11 by amputation and 48 by limb-salvage procedures) and irradiated the primary tumor and bone metastasis of two patients. Only one of the 59 surgical margins was positive for tumor, and this was resected at a second surgery. All 61 patients had adequate open-incisional biopsies at diagnosis. Fifteen patients had primary resection of their tumors and received only postoperative chemotherapy, while 46 had chemotherapy before and after surgery or radiation therapy. Of the 15 patients who only had postoperative chemotherapy from 1980 through 1983, 10 had doxorubicin-high-dose methotrexate and five had doxorubicin-high-dose methotrexate with vincristinebleomycin/cyclophosphamide/dactinomycin (BCD). The 28 patients treated from 1983 through 1987 with preoperative high-dose methotrexate-vincristine-BCD received doxorubicin-cisplatin postoperatively. The 18 patients treated preoperatively from 1987 through 1989 received doxorubicin-cisplatin, to which etoposide-ifosfamide were added postoperatively if response to preoperative chemotherapy was poor. Overall, 20 patients had two drugs (10 received doxorubicin-high-dose methotrexate from 1980 through 1983; 10 received doxorubicin-cisplatin from 1987 through 1989), eight patients had four drugs (doxorubicin-cisplatin and etoposide-ifosfamide from 1987 through 1989), and 33 patients had more than four drugs (high-dose methotrexate, vincristine, BCD, doxorubicin, cisplatin, etoposide, and ifosfamide). We gave chemotherapy to the three patients who had better-differentiated intramedullary osteosarcoma because their tumors were greater than or equal to 10 cm in size (one patient) or greater than or equal to 10 cm in size and metastatic at diagnosis (one patient); despite chemotherapy, two of these three patients subsequently developed metastasis. We determined the amount of tumor necrosis (ജ90% as favorable and <90% as unfavorable) in the 46 patients who had had preoperative chemotherapy (4) and assessed relapse-free and survival rates in the 61 patients from diagnosis to relapse, death, or last follow-up. The times of diagnosis at biopsy or primary resection of the tumors differed from the start of chemotherapy by only 1-2 weeks. On average, we followed living patients through March 1995 and reported their median and range of follow-up times.
P-glycoprotein Multilayer Immunoperoxidase
Although this was a retrospective study, we followed the consensus recommendations for the procedure and methodology of retrospective or prospective clinical correlative drug resistance studies published by Beck et al. (29) from the Memphis Multidrug Resistance Workshop. We scored P-glycoprotein in 98 formalin-fixed tumor samples obtained before treatment (mean, two samples per patient; range, one to four samples) by a previously described sensitive assay (30) . We stained the samples three times with each of the monoclonal anti-Pglycoprotein antibodies, C494 (specific for the MDR1 gene that confers human multidrug resistance) and C219 (recognizes MDR1 as well as MDR3, a gene that is unrelated to multidrug resistance), which are directed against separate Pglycoprotein epitopes, and with immunoglobulin G2a (IgG2a) (isotype-matched negative control for C494 and C219). We confirmed specificity in selected cases with epitope-specific peptides to block antibody binding (31) . Since the assessment of P-glycoprotein expression is qualitative, two observers from different institutions (T. M. Grogan and H. S. L. Chan) interpreted the results separately, masked as to the identity of the samples and to each other's P-glycoprotein scores. The final interpretation was based on the consensus score. We scored samples that contained no P-glycoprotein-positive tumor cells as negative and designated samples with any P-glycoprotein-positive tumor cells as positive. The positive samples were further graded as 1+ to 5+ by the presence of individual tumor cells that had the highest observable level of P-glycoprotein compared with positive (eight-, 16-, 64-, 510-, and 1000-fold multidrug-resistant ovarian carcinoma lines) and negative controls (drug-sensitive parent line), in which staining for P-glycoprotein had been previously standardized by western blot (30) .
Statistical Analysis
Among the 61 patients for whom the observers agreed on the P-glycoprotein status, we did not use an arbitrary cutoff, but relegated those with no positive pretreatment samples to the negative group and those with any detectable Pglycoprotein expression to the positive group because it cannot be presumed that low levels of the protein are irrelevant to the patients' outcomes. We also reported the outcomes for each level of P-glycoprotein rather than for the average level that would be less meaningful because assessment of P-glycoprotein expression of staining is qualitative. We compared the response rates by the Fisher's exact test and estimated the actuarial relapse-free and survival rates by the Kaplan-Meier method (32) . To avoid possible bias by confounding factors, we evaluated the prognostic factors of the patients at diagnosis (tumor size, differentiation, and metastasis) and the amount of tumor necrosis after preoperative chemotherapy for uniformity of distribution in the P-glycoproteinpositive and negative groups and stratified the patients according to each parameter. We determined by logrank analysis if each parameter significantly affected outcome, before and after stratifying for the effect of P-glycoprotein (33) . We similarly assessed the effect of P-glycoprotein directly, after stratifying for each prognostic factor, and after stratifying for all factors simultaneously. We reanalyzed the study population by including the one patient in whom the observers disagreed about the interpretation of P-glycoprotein expression. We also repeated the analysis by excluding the four metastatic patients (two in whom the primary tumor and lung metastasis were resected and two in whom the primary tumor and bone metastasis were irradiated) and three with better-differentiated intramedullary osteosarcoma (one in whom the tumor was ജ10 cm in size, one in whom the ജ10-cm tumor was metastatic at diagnosis, and one without such attributes), similarly stratifying for the relevant prognostic factors. To avoid possible confounding by the type or number of drugs given, we compared outcome for each era with different treatment and for two-, four-, or more than four-drug therapy. To avoid possible selection bias, we evaluated relapse-free and survival rates of all 69 patients from 1980 through 1989 who were eligible by our criteria (see ''Patient Selection''), including the eight in whom pretreatment samples were not retrievable for testing (five from 1980 through 1983, two from 1983 through 1987, and one from 1987 through 1989). All statistical tests were two-sided.
Results
The observers detected P-glycoprotein (Fig. 1, A and B) in 44 tumor samples obtained before treatment (27 patients) but not in 53 other pretreatment samples (34 patients); IgG2a control samples were negative. Since there was disagreement over the interpretation of P-glycoprotein expression in the pretreatment sample from one patient, this patient was excluded from the study population for analysis of outcome. The interobserver consensus score was excellent, with agreement on the Pglycoprotein status of 98% of patients and on whether samples were positive or negative in 89% of instances. We graded samples that showed considerable heterogeneity as 1+ to 3+ for focal or diffuse staining of P-glycoprotein in the plasma membrane and Golgi of tumor cells, but found no 4+ or 5+ samples. None of four initially negative tumors that relapsed were available for retesting. Tumors positive at diagnosis con- tinued to express increased P-glycoprotein at relapse (data not shown).
We found that the P-glycoprotein expression at diagnosis was highly predictive of the response to chemotherapy. We showed that outcome was poor regardless of the level of P-glycoprotein positivity (0% relapse free and 35% surviving), whereas prognosis was favorable with undetectable P-glycoprotein (87% relapse free and 94% surviving). On the basis of P-glycoprotein expression data from all patients, we found that relapses and deaths were as common with 1+ levels of glycoprotein (10% relapse free and 50% surviving) as with 2+ (0% relapse free and 27% surviving) or 3+ levels (0% relapse free and 33% surviving). To obtain large enough numbers and fairly balanced groups for statistical analysis, we correlated outcome with the presence or absence of detectable P-glycoprotein, using the entire group of 61 patients. Overall, the relapse-free rate at a median followup of 8.9 years was higher in the 34 patients in which Pglycoprotein was undetectable than in the 27 with increased P-glycoprotein (87% versus 0%; P<.00001) as was the survival rate (94% versus 35%; P<.00001) (Fig. 2, A and B) . Follow-up times for living patients in this group ranged from 5.6 to 14.6 years. This correlation was similarly observed in the 46 patients that received chemotherapy prior to surgery. In the 23 patients with undetectable P-glycoprotein, the long-term outcome was significantly better than in the 23 with increased P-glycoprotein (relapse-free rates 84% versus 0% and survival rates 91% versus 27% at median follow-up of 8.9 years; P<.00001 and P ‫ס‬ .00002, respectively). In the patients with undectable Pglycoprotein, we also more commonly observed a better histologic response (one with ജ90% tumor necrosis). However, the difference in response based only on the degree of tumor necrosis was of borderline significance (rates, 48% versus 17%; P ‫ס‬ .057).
Even if we included back the one patient for whom the observers disagreed about the interpretation of P-glycoprotein expression at diagnosis, either as a positive case or as a negative case, we found that the outcome remained significantly better with undetectable than detectable P-glycoprotein (P range, .00003 to <.00001, comparing the relapse-free and survival rates for the entire group now consisting of 62 patients and the preoperative chemotherapy group consisting of 47 patients). Also, even if we excluded these six patients, the four who were found to have metastasis at diagnosis (one in whom had both a better differentiated tumor and lung metastasis that were resected, one in whom the undifferentiated tumor and lung metastasis were resected, and two in whom the tumor and bone metastasis were irradiated), and eliminated the three with intramedullary osteosarcomas that were better differentiated (one in whom the tumor was ജ10 cm in size and one in whom the ജ10-cm tumor had metastasized to the lung at diagnosis), we found that the outcome remained significantly better with undetectable than detectable P-glycoprotein (P range, .00004 to <.00001, comparing the relapse-free and survival rates of the remaining group now consisting of 55 patients and preoperative chemotherapy group consisting of 42 patients).
Two patients who were in remission developed secondary cancers. One P-glycoprotein-negative patient who received two drugs developed a malignant fibrous histiocytoma at 9.6 years, but survived. One P-glycoprotein-positive patient who received more than four drugs developed acute lymphoblastic leukemia at 1.8 years and died; this was considered a censored observation in Fig. 2 , A and B.
We found that the improved outcome with undetectable rather than increased P-glycoprotein was not due to differences in the prognostic factors at diagnosis, which were nonuniformly distributed. In the entire group of 61 patients (Table 1) , although size of the tumor was prognostically significant for time to relapse, it was not significant for survival time (P ‫ס‬ .043 and P ‫ס‬ .29, respectively, unstratified analysis). When the effect of size of the tumor was stratified by P-glycoprotein, there was no evidence of a difference in relapse-free or overall survival (P ‫ס‬ .33 and P ‫ס‬ .83). Conversely, when the effect of P-glycoprotein Fig. 2 . Kaplan-Meier curves of the outcome of therapy in 61 patients with osteosarcoma at a median follow-up of 8.9 years. The probability of remaining (A) relapse free and (B) surviving was significantly different, depending on whether pretreatment tumor samples were P-glycoprotein positive or negative (P both <.00001, before and after simultaneously stratifying by tumor size, differentiation, and metastasis). The number of patients at risk at 2, 4, 6, 8, 10, 12, 14, and 16 years are shown in parentheses under the x axis. One P-glycoproteinpositive patient who died of acute lymphoblastic leukemia without relapse of osteosarcoma was considered a censored observation. status was investigated in patients stratified by size of tumor, a highly significant relationship was still seen between the expression of P-glycoprotein and relapse-free and overall survival (P<.00001 for both outcomes). Similarly, the degree of differentiation did not significantly affect the outcome when the patients were either unstratified or stratified by P-glycoprotein, whereas P-glycoprotein status significantly affected outcome in patients stratified by the degree of tumor differentiation (P<.00001, comparing both relapse-free and overall survival). In addition, although the presence or absence of metastasis significantly influenced time to relapse and survival time (P ‫ס‬ .00004 and P ‫ס‬ .024, respectively, unstratified), this difference was lost when the metastatic status was stratified by P-glycoprotein (P ‫ס‬ .077 and P ‫ס‬ .56, comparing relapse-free and overall survival). However, the impact of P-glycoprotein status on relapse-free and overall survival persisted even when stratified by metastasis (P<.00001 for both outcomes) or despite simultaneously stratifying by tumor size, degree of differentiation, and the patient's metastatic status (P<.00001 for both outcomes). In the smaller group of 46 patients treated with preoperative chemotherapy (Table 2) , we examined the effect of P-glycoprotein status and similarly found a better outcome occurring with the undetectable than the increased protein. The outcome remained significantly better even when stratified by each prognostic factor or despite simultaneously stratifying by tumor size, degree of differentiation, and the metastatic status (P<.00001 and P ‫ס‬ .00011, comparing relapse-free and overall survival). We also investigated the effect of P-glycoprotein relative to a favorable (ജ90%) or unfavorable (<90%) initial histologic response to preoperative chemotherapy, since this was nonuniformly distributed (Table  2) . We found that the P-glycoprotein status had a high capacity for predicting outcome, even when stratified by tumor necrosis (P<.00001 and P ‫ס‬ .00024, comparing relapse-free and overall survival). Conversely, although the degree of tumor necrosis per se predicted time to relapse, it did not predict survival time (P ‫ס‬ .028 and P ‫ס‬ .11, respectively, unstratified analysis). Furthermore, when the effect of degree of tumor necrosis was stratified by P-glycoprotein, there was no evidence of a difference in relapse-free or overall survival (P ‫ס‬ .95 and P ‫ס‬ .68).
In addition, we similarly stratified for the relevant prognostic factors in the group of 61 patients after we excluded the four with metastasis at diagnosis and the three with betterdifferentiated intramedullary osteosarcomas (one of whom was also metastatic at diagnosis). We found that the outcomes for this group of 55 patients remained significantly better with undetectable than detectable P-glycoprotein, despite further stratification for tumor size (P<.00005 for comparisons of both the relapse-free and survival rates). We additionally excluded the three patients with metastasis at diagnosis and the one with a better-differentiated intramedullary osteosarcoma from the group of 46 patients treated with preoperative chemotherapy and found the outcome in the remaining 42 patients also to be significantly better with undetectable than detectable Pglycoprotein, despite simultaneously stratifying for tumor size and response to chemotherapy (P<.00005, comparing the relapse-free rate; P ‫ס‬ .0014, comparing the survival rate).
To avoid possible confounding by the era of treatment, we examined this issue but found that the better outcome with undetectable than increased P-glycoprotein was not due to the difference when treatment occurred (Fig. 3, A and B) . These differences in relapse-free rates were highly significant with only postoperative chemotherapy from 1980 through 1983 (91% ver- *O/E ‫ס‬ ratio of observed numbers of failures (relapses and deaths) to extent of exposure to the risk of failure assuming no relationship of the prognostic factor or P-glycoprotein status to outcome. P values are from logrank tests of overall comparisons of failures in the subgroups defined by each prognostic factor. †Three intramedullary osteosarcomas were better differentiated but treated with chemotherapy because one was greater than or equal to 10 cm in size and one was greater than or equal to 10 cm in size and had metastasis at diagnosis; two developed metastasis subsequently despite chemotherapy.
‡Overall P values for the relative relapse rate and relative mortality rate of P-glycoprotein-negative subgroup versus P-glycoprotein-positive subgroup; both P values were <.00001 after simultaneously stratifying for tumor size, differentiation, and metastasis. sus 0%; P ‫ס‬ .00023), and with both preoperative and postoperative chemotherapy from 1983 through 1987 (92% versus 0%; P<.00001) or from 1987 through 1989 (78% versus 0%; P ‫ס‬ .00005). The differences in survival rates in the three time periods, however, were less evident (100% versus 75%, P ‫ס‬ .60; 100% versus 29%, P ‫ס‬ .00033; and 76% versus 22%, P ‫ס‬ .076). Because these subgroups were already small, we could not meaningfully reanalyze each of them after exclusion of patients with metastasis or better-differentiated tumors.
To avoid possible confounding by the types of treatment, we examined this issue but found that the better outcome with undetectable than increased P-glycoprotein was not due to the difference in the type or number of drugs given (Fig. 4, A and B) . These differences in the relapse-free rates were highly significant for two-drug (93% versus 0%; P ‫ס‬ .00002), four-drug (33% versus 0%; P ‫ס‬ .045), or more than four-drug (93% versus 0%; P<.00001) therapy. The differences in survival rates in the three therapy groups were also less evident (100% versus 53%, P ‫ס‬ .092; 33% versus 20%, P ‫ס‬ .28; and 100% versus 35%, P ‫ס‬ .00034) than for relapse. We could not further analyze these small subgroups after exclusion of patients with metastasis or better-differentiated tumors.
To avoid possible selection bias, we examined the outcome irrespective of the expression of P-glycoprotein. Overall, in the 61 study patients (57 nonmetastatic and four metastatic), the actuarial relapse-free rate was 50% (53% for nonmetastatic and 0% for metastatic), while the survival rate was 68% (71% for nonmetastatic and 25% for metastatic), similar to previously reported rates (1) (2) (3) (4) (5) (6) (7) (8) . Also, to avoid possible confounding of results by the untested patients, we examined the total number of patients eligible according to our Patient Selection Criteria who were treated from 1980 through 1989 and compared their outcomes irrespective of the expression of P-glycoprotein. If we included eight patients seen from 1980 through 1989 who were not tested because their pretreatment samples were unavailable, the relapse-free rate for the denominator of 69 patients was 48% (51% for nonmetastatic and 0% for metastatic), while the survival rate was 64% (67% for nonmetastatic and 25% for metastatic). The outcomes were also similar to previously reported rates for the eras and the types of therapy. The relapse-free rates for the 61 study patients from 1980 through 1983, from 1983 through 1987, and from 1987 through 1989 were 67%, 48%, and 39%, respectively, while survival rates were 93%, 64% and 47%; with inclusion of the eight untested patients without available pretreatment samples, the relapse-free rates became 69%, 49%, and 37%, and survival rates became 80%, 63%, and 45%. Also, the relapse-free rates for the 61 study patients treated with two drugs, four drugs, and more than four drugs were 70%, 12%, and 47%, respectively, while survival rates were 82%, 19%, and 70%; with inclusion of the eight untested patients without available pretreatment samples, the relapse-free rates became 64%, 12%, and 46% and survival rates became 74%, 19%, and 67%. Overall, in the small group of 15 patients who only received postoperative chemotherapy, the relapse-free rate was 67% com- *O/E ratio of observed numbers of failures (relapses and deaths) to extent of exposure to the risk of failure assuming no relationship of the prognostic factor or P-glycoprotein status to outcome. P values are from logrank tests of overall comparisons of failures in the subgroups defined by each prognostic factor. †One intramedullary osteosarcoma was better differentiated but treated with chemotherapy; this tumor developed metastasis subsequently despite chemotherapy.
‡Overall P values for the relative relapse rate and relative mortality rate of P-glycoprotein-negative subgroup versus P-glycoprotein-positive subgroup; these P values were <.00001 and .00011 after simultaneously stratifying for tumor size, differentiation, and metastasis. One P-glycoprotein-positive patient (1983 through 1987) who died of acute lymphoblastic leukemia without relapse of osteosarcoma was considered a censored observation. Irrespective of the expression of P-glycoprotein, the overall relapse-free rates in the three eras were 67%, 48%, and 39%, respectively, and survival rates were 93%, 64%, and 47%. At diagnosis, one patient (1980 through 1983) had lung metastasis from a greater than or equal to 10 cm, betterdifferentiated tumor while a second had a better-differentiated tumor; a third patient (1983 through 1987) had bony metastases and was irradiated, while a fourth had lung metastases; a fifth patient (1987 through 1989) had a greater than or equal to 10 cm, better-differentiated tumor, while a sixth had metastasis and was irradiated. Patients in the three eras did not fit exactly into the three treatment groups shown in Fig. 4 . Fig. 4 . Kaplan-Meier curves of the outcome of different types of osteosarcoma chemotherapy. Depending on whether pretreatment tumor samples were Pglycoprotein positive or negative, the probability of remaining relapse free was significantly different for (A) 20 patients at median follow-up of 9.3 years (P ‫ס‬ .00002) who had two-drug therapy (bold curves), also in (A) eight patients at median follow-up of 6.7 years (P ‫ס‬ .045) who had four-drug therapy (fine curves), and (B) 33 patients at median follow-up of 9.3 years (P<.00001) who had a more than four-drug therapy. The number of patients at risk at 2, 4, 6, 8, 10, 12, 14, and 16 years are shown in parentheses under the x axis, with bold lettering corresponding to the bold curves and fine lettering corresponding to the fine curves. One P-glycoprotein-positive patient (>four drugs) who died of acute lymphoblastic leukemia without relapse of osteosarcoma was considered a censored observation. Irrespective of P-glycoprotein expression, overall relapsefree rates in the three therapy groups were 70%, 12%, and 47%, respectively, and survival rates 82%, 19% and 70%. At diagnosis, one patient (two-drug group) had a greater than or equal to 10 cm, better-differentiated tumor, a second patient (four-drug group) had bone metastases and was irradiated, a third patient (>four-drug group) had a better-differentiated tumor, a fourth had bony metastases and was irradiated, a fifth had lung metastases, while a sixth had lung metastases from a greater than or equal to 10 cm, better-differentiated tumor. Patients in the three treatment groups did not exactly fit into the three eras shown in Fig. 3 . pared with 43% in the 46 patients who received both preoperative and postoperative chemotherapy; survival rates in these two groups were 93% and 59%, respectively.
Discussion
Conventional osteosarcoma therapy consists of controlling the primary tumor by amputation, limb-salvage surgery, or intraarterial cisplatin and of eradicating micrometastasis with adjuvant chemotherapy (1) (2) (3) (4) (5) (6) (7) (8) . Chemotherapy is essential for curing osteosarcoma, as shown by recent multi-institutional randomized trials (1,2) . The verdict, however, is not yet in for the possible benefit of preoperative neoadjuvant chemotherapy (3). Since conventional prognostic factors have not been useful for predicting the response to chemotherapy (4), we need to look for better predictors, such as the presence of proteins that can confer refractoriness to drugs. P-glycoprotein is the first multidrug resistance protein to be characterized and is relevant to the failure of chemotherapy in many cancers (10) (11) (12) (13) (14) (15) . Because multidrug resistance reversal trials have already been initiated for many cancers including osteosarcoma, it is highly pertinent to ask if increased P-glycoprotein causes chemotherapy to fail in patients with osteosarcoma. Modulating the function of P-glycoprotein with cyclosporine or verapamil has been reported to be associated with enhanced chemotoxicity (14, (22) (23) (24) (25) (26) , probably because the drug resistance protein is widely expressed in such normal tissues as kidney, liver, gut, hematopoietic cells, and stem cells (34) (35) (36) . P-glycoprotein fulfills crucial physiologic functions in these normal tissues, such as conferring protection against toxins at the blood-brain barrier or regulating phosphatidylcholine secretion into bile, as shown by the creation of knockout mice homozygous for the disrupted mdr1a and mdr2 genes (homologues of human MDR1 and MDR3 genes) (37, 38) . Furthermore, cyclosporine alters the metabolism of cytotoxins, thereby enhancing their chemotoxicity by increasing the systemic drug exposure (24, 25) . Therefore, to justify the use of relatively toxic pharmacologic inhibitors for modulating the function of Pglycoprotein, it is necessary to establish that the protein affects the patient's response to osteosarcoma therapy and to prospectively select those patients who have a poor prognosis because their tumors overexpress this protein.
The Southern blot technique cannot be used for Pglycoprotein correlative studies because the gene is not amplified in clinical samples and the western blot method lacks the sensitivity needed to study the heterogeneous expression of Pglycoprotein in tumors. Northern blot and reverse transcriptionpolymerase chain reaction techniques are sensitive, but MDR1 messenger RNA (mRNA) levels may not necessarily correlate with those of the protein (39, 40) . These assays also cannot distinguish between MDR1 mRNA expressed in malignant cells and MDR1 mRNA expressed in the stromal cells or hematopoietic cells that normally infiltrate tumors (19) . Morphologic examination is a practical way to make this distinction and may also differentiate between the P-glycoprotein in the plasma membrane and other cross-reacting, nonmembrane proteins that have been reported, such as a 200-kd protein that migrates with myosin or the mitochondrial enzyme pyruvate carboxylase (41, 42) . For these reasons, we have elected to score this protein in single tumor cells by an immunohistochemical method. We have standardized our assay against well-characterized negative and positive cell lines with known P-glycoprotein contents, including the low-resistance control SKVCR 0.015, to ensure that the assay is sensitive enough to detect low P-glycoprotein levels and small numbers of positive tumor cells. We have additionally optimized the signal-to-noise ratio for detecting P-glycoprotein by refining the tissue preparation and staining methods (30) .
In this immunoperoxidase method, we have confirmed specificity by using epitope-specific peptides together with two antibodies directed against separate P-glycoprotein epitopes (31) , as recommended by the Memphis Multidrug Resistance Workshop (29) . Since our ultimate goal is to study clinical samples rather than cell lines, we have elected to focus on C494 and C219 for these reasons. C494 and C219 are two fully characterized monoclonal antibodies with separate internal linear epitopes that have been mapped to the resolution of a single amino acid (31) . The binding of P-glycoprotein by C494 and C219 has been shown to be less sensitive to conformational changes and environmental effects than antibodies against other external epitopes (MRK-16, HYB-241, UIC2, and 4E3) or epitopes that are probably internal (JSB-1), of which only MRK-16 has been mapped (43) . For instance, because MRK-16 has a discontinuous epitope separated by approximately 625 amino acids that encompasses the first and fourth of six predicted extracellular peptide loops of P-glycoprotein, binding is influenced by the protein's glycosylation state and by high salt (43) . Also, unlike the other antibodies, because C494 and C219 work well in fixed cells and against partially degraded P-glycoprotein, spurious variations are less likely to be observed during the study of patient samples. Furthermore, we have shown the suitability of C494 and C219 for creating assays in which multiple layers of secondary antibodies are used to enhance the primary signal for P-glycoprotein, and hence that are sensitive enough for the early diagnosis of multidrug resistance in clinical samples (11, 12) . Although C494 is known to be specific for the MDR1 gene that confers human multidrug resistance and C219 recognizes both the MDR1 and MDR3 genes, such data are not clearly defined for the other antibodies. Since Beck et al. (29) have recommended that clinical samples be studied with two separate-epitope antibodies for confirmation and we have found that C219 staining concurs with C494 staining, this suggests that the MDR1 protein is detected rather than just the MDR3 protein (11, 12) and that it is valid to employ C219 for corroboration, even if it is not absolutely specific for MDR1.
We have interpreted samples by strict criteria, calling only staining of a distinct plasma membrane with or without Golgi as positive, because solely cytoplasmic staining may be due to cross-reacting proteins (41, 42) . We require that P-glycoprotein be present in the tumor cells rather than just in the normal stromal cells or hematopoietic cells (34) (35) (36) . Because defining the P-glycoprotein-positive and -negative groups is still a contentious issue, we prefer designating only samples with undetectable P-glycoprotein as negative and those samples with any detectable P-glycoprotein as positive so as not to presume that a low level of P-glycoprotein expression or a small number of positive tumor cells is irrelevant to outcome. To ensure that the clinical correlations are meaningful, we have correlated outcome with P-glycoprotein expression before treatment rather than at relapse to avoid possible confounding by the unfavorable effect of relapse and stratified the results for the different therapies and prognostic factors, particularly the tumor stage, which profoundly affects outcome. Because osteosarcoma may relapse late (8), we have assessed patients who have been followed for 5 years or more to ensure that the outcome data are accurate. Our excellent interobserver consensus score and highly significant correlations attest to the importance of a scrupulous, unequivocal P-glycoprotein assay, strict criteria for the interpretation of clinical samples, and the use of rigorous study methodology (29) .
Several other observations in this study may have clinical relevance. We have found that any detectable overexpression of P-glycoprotein at diagnosis was correlated with a statistically significant failure of chemotherapy, whereas undetectable Pglycoprotein correlated with lasting remission. Since Pglycoprotein appears to be rate limiting for responses to osteosarcoma therapy, this confirms the crucial role of chemotherapy in eradicating the micrometastases that are probably present in most patients at diagnosis. We have found that P-glycoprotein expression predicts outcome better than conventional risk factors, such as tumor size, differentiation, and the metastatic status, more accurately than the degree of tumor necrosis with preoperative chemotherapy, and its impact outweighs the effect of different types of chemotherapy from different treatment eras. Thus, our study corroborates the pilot osteosarcoma MDR1 mRNA data of others (19, 20) and the data of Baldini et al. (21) that show that increased levels of this drug-resistance protein correlate with a significantly increased risk of adverse events, independent of the extent of necrosis after preoperative osteosarcoma chemotherapy. The effect of P-glycoprotein is apparently more striking on the relapse-free rate than survival rate, perhaps reflecting that this disease is often associated with prolonged survival despite relapse if lung metastases are aggressively resected (44) . Since our approach has always been to resect metastases aggressively, we have performed 54 metastectomies (mean, two procedures per patient; range, one to five procedures) of the lung (46), bone (five), and other sites (three) in the four patients with metastasis at diagnosis and the 26 who exhibited metastasis subsequently. Six of the metastectomies were in five patients diagnosed from 1980 through 1983, 20 in 14 patients diagnosed from 1983 through 1987, and 28 in 11 patients diagnosed from 1987 through 1989. Ten of the patients had one mastectomy, seven had two, four had three, two had four, and two had five; only five patients never had metastectomies.
We have observed increased P-glycoprotein levels in 44% of the patients with osteosarcoma before treatment, particularly in those with tumors greater than or equal to 10 cm in size (60%) or with tumors associated with metastatic disease (100%), as has been described previously for rhabdomyosarcoma, neuroblastoma, and colon carcinoma (11, 12, 45) . It is not known if Pglycoprotein is expressed independently in osteosarcoma or coincidentally with other potentially unfavorable biologic factors, such as hyperdiploidy (28) , p53 or retinoblastoma (RB1) gene mutations (46, 47) , c-myc gene amplification (48) , or allelic loss on chromosomes 3q, 13q, 17p, or 18q (49) . Investigators (10) (11) (12) (13) (14) (15) have concluded that, in many cancers, undetectable Pglycoprotein before treatment correlates with a low recurrence rate, implying that the subsequent acquisition of P-glycoprotein or another drug-resistance protein may not be common. However, if tumors initially negative for P-glycoprotein do relapse, the protein usually becomes detectable (11, 12) , although this has not been examined in the present study. Conversely, increased P-glycoprotein before treatment correlates with a high recurrence rate, with the tumors that relapse continuing to overexpress P-glycoprotein, sometimes at even higher levels (10) (11) (12) (13) (14) (15) . It is not known if P-glycoprotein alone or P-glycoprotein together with another drug-resistance mechanism contributes to the failure of chemotherapy. The clinical significance of other such proteins, including the multidrug resistance protein, lung resistance protein, glutathione enzymes, or topoisomerase II, is poorly defined at present for osteosarcoma (50) (51) (52) (53) .
We have found that the expression of P-glycoprotein predicts outcome more accurately than the amount of tumor necrosis from preoperative chemotherapy. Furthermore, tumor necrosis no longer predicts outcome after stratifying for P-glycoprotein, whereas P-glycoprotein remains significantly predictive of the outcome, despite stratifying for tumor necrosis. One possible explanation is that the presence of drug-resistant micrometastases is more detrimental to the patient's long-term outcome than is the presence of a refractory primary tumor that can be totally resected. Alternatively, decreased tumor necrosis may sometimes be due to local factors, such as poor penetration of drugs into bone or suboptimal drug delivery into large necrotic tumors, rather than to nonresponse to chemotherapy. This issue is presently unresolved because one study has found that the amount of tumor necrosis from preoperative chemotherapy does not correlate well with the therapeutic outcome (54) . Yet, other studies (3) (4) (5) have reported a correlation between tumor necrosis and the outcome of chemotherapy. It has been observed that the chemotherapy response of the primary tumor may differ from that of the metastasis, and that different sites of metastasis may respond differently to treatment (55) .
We have found that the expression of P-glycoprotein predicts outcome irrespective of the type or number of drugs given (two, four, or more than four drugs). Additional drugs that are substrates of P-glycoprotein (doxorubicin, vincristine, dactinomycin, and etoposide) or nonsubstrates (high-dose methotrexate, bleomycin, cyclophosphamide, ifosfamide, and cisplatin) fail to improve the outcome of patients with P-glycoprotein-expressing tumors. This suggests that P-glycoprotein substrates are a crucial component of osteosarcoma therapy and cannot be replaced by drugs that are not substrates of the protein. At the clinical level, this issue remains unresolved, with one study (54) reporting benefit from intensifying the postoperative chemotherapy for poor responders, but other studies (7, 8) failing to salvage refractory patients by adding alternative chemotherapies. Although published data that show that patients without initial detectable P-glycoprotein seldom relapse suggests the rarity of another drug-resistance mechanism (10) (11) (12) (13) (14) (15) , this finding may not apply for those with detectable P-glycoprotein before treatment. In these newly diagnosed P-glycoprotein-positive patients, it is possible that additional forms of drug resistance are already present that prohibit their being rescued by drugs that are nonsubstrates of P-glycoprotein, such as ifosfamide and cisplatin.
In this study, the patients who were treated with chemotherapy only after surgery appeared to do better than those who had surgery and postoperative chemotherapy following preoperative chemotherapy. Our group of 15 patients in this category is too small for any firm conclusion to be drawn, although one study (3) has previously reported a similar finding. It is noteworthy that other trials that gave both preoperative and postoperative chemotherapy have failed to improve on the results of the Multi-Institutional Osteosarcoma Study, in which chemotherapy was only given after surgery (2) . Although some published data (2, 3) and the therapeutic outcome in our few patients suggest that patients with refractory osteosarcoma might do better with surgery upfront to give drug-resistant tumor cells less chance to metastasize, such a conclusion can only be made based on a study of a large cohort. Our data suggesting that intensifying postoperative chemotherapy does not improve the outcome of patients with P-glycoprotein-expressing tumors are supported by clinical findings from other investigators (7, 8) . Therefore, the early application of alternative therapy may be crucial for the salvage of these refractory patients. Such therapy might include immunomodulation by liposomal muramyl tripeptide phosphatidylethanolamine (56) , targeting resistant cells with toxin-and radionuclide-labeled anti-P-glycoprotein antibodies or antiosteosarcoma antibodies (57, 58) , or rescuing patients by autologous bone marrow transplantation after high-dose chemotherapy (59). Since we have found that P-glycoprotein expression before treatment is a critical determinant of the long-term response to osteosarcoma therapy, irrespective of the chemotherapy type and independent of conventional prognostic factors, we suggest that measuring P-glycoprotein prospectively may identify those patients likely not to respond well to therapy, in whom early intervention with these toxic experimental modalities, including the use of P-glycoprotein inhibitors similar to verapamil or cyclosporine that accentuate chemotoxicity (14, (22) (23) (24) (25) (26) (27) , can be justified.
